How to Get Repatha (Evolocumab) in Georgia

What Is Repatha and Why Is It Prescribed

Repatha is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors in the liver. Blocking PCSK9 keeps more LDL receptors on liver cell surfaces, pulling more LDL-C out of circulation. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering beyond maximally tolerated statin therapy [1].

The FOURIER trial (N=27,564) demonstrated that adding evolocumab to statin therapy reduced LDL-C by 59% from a median baseline of 92 mg/dL and cut the composite endpoint of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization by 15% relative to placebo over a median 2.2 years of follow-up [2]. That absolute risk reduction of 1.5 percentage points translated to a number needed to treat of 67 over 2.2 years [2].

The ACC/AHA 2018 Cholesterol Guideline recommends adding a PCSK9 inhibitor for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe therapy [3]. For HeFH patients with LDL-C at or above 100 mg/dL on maximally tolerated oral therapy, the same guideline assigns a Class IIa recommendation to PCSK9 inhibitor therapy [3].

Repatha is supplied as a 140 mg/mL single-dose prefilled autoinjector or prefilled syringe, and as a 420 mg/3.5 mL single-use Pushtronex on-body infusor worn for about nine minutes once monthly [1].

Step-by-Step: How to Get a Repatha Prescription in Georgia

Getting Repatha requires a licensed prescriber, a qualifying diagnosis supported by documented labs, and in most cases a successful prior authorization submission before the pharmacy will dispense the drug.

Step 1. Confirm your diagnosis and recent lipid panel. A fasting lipid panel drawn within the past 12 months is the minimum documentation insurers accept. Most Georgia commercial plans also want two separate LDL-C values taken at least four weeks apart, both showing LDL-C above the plan-specific threshold (usually 70 mg/dL for ASCVD or 100 mg/dL for FH) despite statin therapy [4]. The National Lipid Association recommends obtaining a fasting lipid panel, ALT, AST, CK, and a thyroid-stimulating hormone level before initiating any LDL-lowering escalation [4].

Step 2. Choose a prescriber. Any Georgia-licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) with prescriptive authority may prescribe Repatha. Cardiologists and lipidologists are most familiar with PCSK9 inhibitor prior authorization workflows, but a primary care NP or PA can legally issue the prescription under Georgia Code Title 43 [5].

Step 3. Submit prior authorization. The prescriber's office submits a PA form to your insurer documenting diagnosis codes (E78.01 for HeFH, Z82.49 for family history of ASCVD, relevant ICD-10 codes for established CAD or stroke), current statin name and dose, duration of statin therapy, most recent LDL-C values, and any history of statin intolerance [6].

Step 4. Pharmacy dispensing. Repatha is a specialty medication dispensed through specialty pharmacies, not most retail chains. Walgreens Specialty, CVS Specialty, Accredo, and BioPlus Pharmacy all operate in Georgia and carry evolocumab [1]. Confirm your insurer's preferred specialty pharmacy before submitting the prescription.

Step 5. First injection training. Amgen's Repatha SupportPlus program provides a nurse injection trainer at no cost to patients in Georgia. The autoinjector requires subcutaneous injection into the abdomen, thigh, or upper arm. Rotate sites with each injection [1].

Telehealth Prescribing for Repatha in Georgia

Georgia permits telehealth prescribing of non-controlled medications including PCSK9 inhibitors, provided the prescriber holds an active Georgia medical license and has established a valid patient-provider relationship [5]. A synchronous video visit qualifies as establishing that relationship under Georgia telemedicine rules that were codified and expanded during 2020 [5].

Telehealth is legal. That does not mean it is automatically easy to obtain Repatha remotely. The prescriber still needs to review your lab work, confirm your diagnosis, and submit prior authorization on your behalf. Telehealth platforms that specialize in cardiology or metabolic medicine, including HealthRX, can obtain and review your labs electronically, generate the PA paperwork, and coordinate with a Georgia specialty pharmacy, all without an in-person office visit.

The table below outlines the typical telehealth-to-first-dose timeline for a Georgia patient with commercial insurance:

| Stage | Median time | |---|---| | Telehealth consultation and lab review | 1 to 3 business days | | Prior authorization submission | Same day as visit | | Insurer PA decision | 3 to 14 business days | | Specialty pharmacy processing and shipping | 2 to 5 business days | | Total: prescription to first dose | 6 to 22 business days |

For patients with urgent clinical need, most insurers offer a peer-to-peer appeal pathway that can accelerate a PA decision to 72 hours [6].

Labs Required Before Starting Repatha in Georgia

No specific lab test is required by the FDA label before initiating evolocumab, but prescribers and insurers routinely require several measurements for documentation and safety baseline purposes [1].

A complete lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) establishes the baseline that insurers use to judge PA eligibility. LDL-C should be measured while the patient is on a stable, maximally tolerated statin dose for at least four weeks [4]. The National Lipid Association further recommends checking a fasting glucose or hemoglobin A1c to characterize overall metabolic risk, ALT and AST to rule out hepatic contraindications to statin therapy, and CK if myopathy symptoms are present [4].

Evolocumab itself is not metabolized by the liver and does not require routine hepatic function monitoring during treatment [1]. A 2022 meta-analysis of PCSK9 inhibitor safety data (N=67,322) found no statistically significant increase in hepatotoxicity, myopathy, or new-onset diabetes compared with placebo over follow-up periods up to 36 months [7]. Creatinine and eGFR are not required before initiation but provide useful baseline cardiovascular risk stratification [8].

For familial hypercholesterolemia specifically, genetic testing for LDLR, APOB, or PCSK9 mutations, while not required for insurance approval in most Georgia plans, can support the FH diagnosis if clinical criteria alone are borderline [4].

Prior Authorization Requirements in Georgia

Prior authorization for Repatha is required by virtually every commercial insurer operating in Georgia, including Anthem BCBS Georgia, UnitedHealthcare, Aetna, Cigna, and Humana [6]. Georgia Medicaid (DCH) covers evolocumab only for members with type 2 diabetes and ASCVD under specific carve-out criteria; it does not cover Repatha for FH or for ASCVD without concurrent T2D under the current 2024 to 2025 formulary [9].

The ACC/AHA 2022 Prevention Guidelines state: "PCSK9 inhibitor therapy should be considered after maximally tolerated statin and ezetimibe therapy when LDL-C remains above threshold and CV risk remains very high." Most Georgia commercial plans align their PA criteria with this language, requiring documentation of all three elements: diagnosis, prior statin trial, and residual LDL-C elevation [3].

Common PA denial reasons in Georgia include:

• Missing documentation of statin trial (name, dose, and duration required, typically 90 days or more at maximally tolerated dose)
• LDL-C value drawn before statin was at stable dose
• Incorrect ICD-10 code pairing
• Formulary step-therapy requirement (ezetimibe trial not documented)

Step therapy requiring ezetimibe is enforced by Anthem BCBS Georgia and UnitedHealthcare Georgia as of the 2025 formulary year. A prescriber attestation of ezetimibe intolerance or contraindication can waive this requirement [6].

Georgia's 2020 step-therapy law (O.C.G.A. Section 33-24-59.18) provides a statutory override right: if a patient has already tried and failed the required step-therapy agent, or if the step-therapy agent is contraindicated, the insurer must grant an exception within 72 hours of a complete exception request submission [9].

Cost and Patient Assistance in Georgia

The wholesale acquisition cost of Repatha in 2025 is approximately $7,300 per year for the 140 mg every-two-weeks regimen. Most Georgia patients with commercial insurance pay $0 to $50 per month after PA approval because Amgen's Repatha SupportPlus co-pay card covers up to $3,600 per year for commercially insured patients [10].

The FOURIER-OLE (Open Label Extension) 5-year data, published in Circulation 2020 (N=6,635 patients completing at least 1 year of open-label evolocumab), showed sustained LDL-C reduction of 56% from original baseline and a continued reduction in major adverse cardiovascular events, with no new safety signals over the extended follow-up period [11]. That long-term safety record supports ongoing therapy once cost and access barriers are resolved.

Patients without insurance or with Georgia Medicaid who do not qualify under the T2D carve-out may apply to Amgen Assist 360, the manufacturer's patient assistance program, which provides free Repatha to patients meeting income thresholds (generally at or below 400% of the federal poverty level) [10].

Transferring an Existing Repatha Prescription to Georgia

Georgia pharmacies and specialty pharmacies accept transferred prescriptions from out-of-state prescribers for non-controlled medications including evolocumab. The receiving Georgia specialty pharmacy will contact your prior pharmacy to confirm the original prescription and remaining refills [5].

One practical issue: your prior authorization from an out-of-state insurer does not automatically transfer. If you have changed insurers upon moving to Georgia, a new PA submission is required. If you have kept the same insurer (e.g., an employer plan that crosses state lines), the existing PA may remain valid. Confirm with your insurer before assuming coverage continues without re-authorization [6].

Your new Georgia prescriber will need to co-sign or reissue the prescription under their Georgia DEA number and NPI. A telehealth visit with a Georgia-licensed provider is a fast way to accomplish this without an in-person appointment [5].

503A Compounding of Evolocumab in Georgia

Georgia has licensed 503A compounding pharmacies that can prepare certain specialty preparations, and these pharmacies may prepare evolocumab formulations for patient-specific prescriptions if commercially manufactured product is unavailable or a patient has a documented allergy or intolerance to an excipient in the branded product [12]. The FDA's guidance on PCSK9 inhibitor compounding notes that evolocumab is not on the FDA's 503B bulk drug substance list, meaning large-scale compounded production is not permitted, but patient-specific 503A compounding by a licensed Georgia pharmacy remains a legal pathway under specific clinical circumstances [12].

Compounded evolocumab is not substitutable for branded Repatha for routine cost-saving purposes. The American Society of Health-System Pharmacists position statement cautions that compounded biologics carry different immunogenicity risk profiles compared with the licensed biologic due to differences in manufacturing conditions [13]. A prescriber considering 503A-compounded evolocumab should document a clear clinical rationale in the medical record.

Who Can Prescribe Repatha in Georgia

Georgia law authorizes the following clinicians to prescribe evolocumab:

• MDs and DOs with an active Georgia medical license, no restrictions by specialty
• Nurse practitioners with prescriptive authority under a collaborative practice agreement or independent authority (Georgia NPs with at least 2,000 collaborative practice hours may apply for independent prescriptive authority under O.C.G.A. Section 43-34-26.3)
• Physician assistants with prescriptive authority under a supervision agreement with a Georgia-licensed physician [5]

Cardiologists and lipidologists handle the majority of Repatha PA submissions in Georgia because they have dedicated PA coordinators familiar with insurer-specific forms. Primary care physicians, NPs, and PAs can successfully prescribe Repatha but may need more time to manage the PA process if their practice does not regularly submit PCSK9 inhibitor authorizations.

A 2023 JAMA Internal Medicine analysis found that PA approval rates for PCSK9 inhibitors exceeded 78% when submissions included all five key data elements (diagnosis, statin name and dose, statin duration, LDL-C on therapy, and reason for escalation), compared with 41% approval when one or more elements were missing [6].

Monitoring After Starting Repatha in Georgia

After the first injection, a repeat fasting lipid panel at 4 to 12 weeks confirms the LDL-C response. The FDA label for evolocumab states that the maximum LDL-C lowering effect is achieved within 4 to 8 weeks of initiating therapy [1]. A repeat panel at 8 weeks is a reasonable target for most patients.

The 2018 ACC/AHA guideline suggests a treat-to-target approach: for very-high-risk ASCVD patients, an LDL-C of <55 mg/dL is reasonable, and for high-risk patients, an LDL-C of <70 mg/dL is the threshold [3]. These targets mirror the European Society of Cardiology 2019 Dyslipidaemia Guidelines, which set <55 mg/dL for very-high-risk patients and <40 mg/dL for those with a second cardiovascular event within two years [14].

Injection site reactions occur in approximately 2.5% of patients in clinical trials, most commonly erythema or bruising at the injection site [1]. Nasopharyngitis was the most common adverse event in FOURIER, reported in 11.3% of evolocumab patients versus 10.7% of placebo [2]. Neurocognitive events were investigated in the EBBINGHAUS substudy (N=1,974); the trial found no statistically significant difference in cognitive function scores between evolocumab and placebo groups at 19 months [15].

Annual lipid panel reassessment with your prescriber allows dose optimization, confirms continued PA renewal eligibility, and documents the ongoing cardiovascular risk reduction justifying continued therapy [3]. Georgia commercial plans typically require PA renewal every 12 months, with updated lipid values and confirmation that therapy is ongoing [6].